Former Riley Hospital CEO Pescovitz to join Eli Lilly
Dr. Ora Pescovitz is returning to Indianapolis after spending the past five years as CEO of the University of Michigan Health System.
Eli Lilly and Co.
Articles
Lilly consolidated into testosterone drug lawsuit
The decision to collect cases before one court comes after the U.S. Food and Drug Administration said it will re-examine the safety of testosterone-replacement drugs after studies showed the medicine posed an increased risk of heart attack and stroke.
Costly drugs force cancer docs to weigh price with therapy
With new cancer drugs priced as high as $10,000 a month, and insurers tightening payment rules, patients who thought they were well covered increasingly find themselves having to make life-altering decisions about what they can afford.
Lilly, Sanofi seek to sell erection drug Cialis without prescription
Sanofi will apply for approval of Cialis as an over-the-counter treatment in the United States, Europe, Canada and Australia. The drug garnered $2.16 billion in sales last year.
Ex-Lilly partner wins latest suit over Actos’ cancer risk
Takeda Pharmaceutical was found not liable for the bladder cancer of two women who used its Actos diabetes medication in the company’s latest trial over the drug. Actos was marketed for Takeda in the United States by Eli Lilly and Co. from July 1999 to March 2006.
Takeda denies hiding Actos cancer risks in Nevada trial
Takeda Pharmaceutical Co. didn’t hide the alleged bladder-cancer risks of its diabetes medicine Actos, a lawyer for the company told a jury. Actos was marketed for Takeda in the United States by Eli Lilly and Co. from July 1999 to March 2006.
Drugmaker hid diabetes drug’s cancer risks, lawyer says
Takeda Pharmaceutical Co. executives covered up the cancer risks of its diabetes medicine Actos to protect billions of dollars in sales, a lawyer for two women argued.
UPDATE: AstraZeneca board rejects new offer from Pfizer
Pfizer’s proposed deal would have been the richest acquisition ever among drugmakers and the third-biggest deal in any industry, according to figures from research firm Dealogic.
Lilly’s latest sales strategy: the soft sell
Eli Lilly and Co. thinks it has a secret weapon to return to growth. No, it’s not a new blockbuster drug—although Lilly will most likely have several new products hit the market this year and next. Rather, it’s an unorthodox, softer approach put into play by its U.S. sales force.
Lilly CEO elected chairman of United Way Worldwide board
United Way Worldwide President and CEO Brian Gallagher said John Lechleiter will help strengthen the not-for-profit network's capacity to meet growing human needs around the world.
Lilly to appeal $450M ruling over poisoned workers in Brazil
Brazilian federal prosecutors had accused a Lilly subsidiary of incinerating toxic waste at the plant that it operated until 2003.
Lilly says its once-daily insulin tops competitor’s drug
Eli Lilly & Co. said its experimental insulin helped diabetic patients more than Sanofi’s biggest product in studies that also raised some safety risks.
U.S. House votes to revive expired research tax credit
The 274-131 vote follows calls to restore the credit by a coalition of companies including Indianapolis-based Eli Lilly and Co. and Texas Instruments Inc.
Bayer’s $14.2 billion Merck buy shows pharma strategy split
Bayer AG’s $14.2 billion acquisition of Merck & Co. is the latest in a series of big pharma deals and it exposes a deepening split in the way drugmakers approach their portfolios.
Drug prices surge as generics, niche treatments eat profit
Since 2007, the cost of brand-name medicines has jumped, with prices doubling for dozens of established drugs that target everything from multiple sclerosis to cancer, blood pressure and even erections, according to an analysis conducted for Bloomberg News.
Lilly Endowment sells Lilly stock for first time since ’08
Indianapolis-based Lilly Endowment sold 150,000 shares of Eli Lilly and Co. stock on Monday, resuming a short-lived asset diversification plan suspended when stock prices swooned in 2008.
Lilly trade-secret defendants released to home detention
The court noted that after the government filed a second indictment March 12, the trade-secret theft claims against Guoqing Cao and Shuyu Li were changed to wire fraud, and aiding and abetting and conspiracy to commit wire fraud.
Lilly’s quarterly profit meets analyst expectations
The drugmaker, which is weathering patent expirations, saw sales fall more slowly than expected for its antidepressant Cymbalta.
Investor pressure pushing drugmakers to make deals
Tuesday’s blockbuster deal involving Indianapolis-based Eli Lilly and Co. was just the latest of several that have taken place since the beginning of the year.
Lilly to pay dearly for Novartis animal health biz
Wall Street analysts raised their eyebrows at the hefty price Eli Lilly and Co. will pay to acquire Novartis Animal Health, when compared to the value of the biggest player in the field.